Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
2/26/2024 | $23.00 | Market Perform | Leerink Partners |
2/20/2024 | Hold → Reduce | HSBC Securities | |
1/3/2024 | $21.00 | Underweight | Barclays |
12/22/2023 | $27.00 | Hold | HSBC Securities |
10/23/2023 | $27.00 → $30.00 | Neutral → Overweight | JP Morgan |
7/3/2023 | $37.00 → $27.00 | Underweight | Morgan Stanley |
6/28/2023 | $46.00 → $34.00 | Buy → Hold | Deutsche Bank |
2/23/2023 | $45.00 | Buy | Loop Capital |
13F-HR - Walgreens Boots Alliance, Inc. (0001618921) (Filer)
8-K - Walgreens Boots Alliance, Inc. (0001618921) (Filer)
SCHEDULE 13D/A - Walgreens Boots Alliance, Inc. (0001618921) (Filed by)
Transaction Highlights Walgreens Boots Alliance announces early settlement of certain prepaid variable share forward transactions with respect to shares of Cencora for delivery of an aggregate 6.1 million shares Concurrent with the early settlement, the Company executed a sale of the remaining 1.3 million shares of Cencora pledged under the early settled contracts. The Company receives approximately $300 million from the early settlement and the concurrent sale of shares Following today's early settlement, the Company owns approximately 12.6 million shares of Cencora pledged under the remaining prepaid variable share forward contracts, which have the potential to provide additional
Walgreens Boots Alliance, Inc. (NASDAQ:WBA) today announced that its board of directors is suspending the company's cash dividend historically paid to stockholders on a quarterly basis, as management continues to evaluate and refine its capital allocation policy consistent with the company's broader long-term turnaround efforts. This change in capital allocation is aimed at strengthening WBA's balance sheet by reducing debt over time and improving free cash flow, as the company works toward achieving a retail pharmacy-led turnaround underpinned by a sustainable economic model. The company's cash needs over the next several years, including with respect to litigation and debt refinancing,
Company moves earnings date with Securities and Exchange Commission and U.S. stock markets closed on January 9, the previously scheduled date, in honor of late former President Jimmy Carter Walgreens Boots Alliance, Inc. (NASDAQ:WBA) will release its fiscal year 2025 first quarter results at 7 a.m. ET on Friday, January 10, followed by a one-hour conference call with WBA management beginning at 8:30 a.m. ET. The company today announced it is moving the previously scheduled earnings date of January 9 back one day, as the Securities and Exchange Commission and U.S. stock markets will be closed on the 9th in observance of a national day of mourning for former President Jimmy Carter. The
SC 13G/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)
SC 13D/A - Walgreens Boots Alliance, Inc. (0001618921) (Filed by)
SC 13G/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)
Leerink Partners initiated coverage of Walgreens Boots Alliance with a rating of Market Perform and set a new price target of $23.00
HSBC Securities downgraded Walgreens Boots Alliance from Hold to Reduce
Barclays initiated coverage of Walgreens Boots Alliance with a rating of Underweight and set a new price target of $21.00
Latest data shows high levels of flu in most states, including significantly higher flu activity across the country when compared to the same time last year The Walgreens Flu Index has tracked its fourth consecutive week of increasing flu activity, with most states across the country experiencing high levels of flu. Overall, U.S. flu activity over the last four weeks is significantly higher when compared to the same time last year – flu activity from the week ending February 8, 2025, was 204% higher compared to the week ending February 10, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250214616891/en/For 11 years, the W
Transaction Highlights Walgreens Boots Alliance announces early settlement of certain prepaid variable share forward transactions with respect to shares of Cencora for delivery of an aggregate 6.1 million shares Concurrent with the early settlement, the Company executed a sale of the remaining 1.3 million shares of Cencora pledged under the early settled contracts. The Company receives approximately $300 million from the early settlement and the concurrent sale of shares Following today's early settlement, the Company owns approximately 12.6 million shares of Cencora pledged under the remaining prepaid variable share forward contracts, which have the potential to provide additional
The Council's first year delivers tangible solutions to strengthen pharmacy talent pipeline and transform the future of pharmacy. Today marks a milestone for Walgreens as it looks back on the progress made over the last year since the launch of the Walgreens Deans Advisory Council, formed with the goal of enhancing the pharmacy profession and advancing solutions to attract, recruit and create a dynamic workplace for current and future pharmacists. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250204745680/en/Deans of pharmacy gather for an in-person meeting with Walgreens leadership team to discuss progress on the objectives
4 - Walgreens Boots Alliance, Inc. (0001618921) (Reporting)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
Stenta will lead B2B commercial growth strategy as the company strengthens its role as the first choice for community pharmacy and health services in the U.S. Walgreens, an integrated healthcare, pharmacy and retail leader serving millions of customers and patients every day, today announced the appointment of Jason Stenta as SVP and chief commercial officer. In this new role, Stenta will lead the company's commercial growth strategy, driving development and commercialization of B2B healthcare services built on the company's core assets, and enhancing partnerships with payers, health system providers and life sciences companies. This press release features multimedia. View the full release
Names Tracey Koller as Chief Merchandising Officer and Sharmila Sudhakar as Group Vice President and Head of Digital Commerce Walgreens, the leading independent retail pharmacy and healthcare provider, today announced two key leadership appointments: Tracey Koller, senior vice president and chief merchandising officer, and Sharmila Sudhakar, group vice president and head of Walgreens digital commerce. The company believes these new appointments will significantly contribute to its efforts with regard to the turnaround of the business as the company focuses on enhancing the front of store and omnichannel experience for its customers while driving in-store efficiencies. This press release
NEW YORK, July 12, 2024 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that Super Micro Computer Inc. (NASDAQ:SMCI), will become a component of the Nasdaq-100 Index® (NASDAQ:NDX) and the Nasdaq-100 Equal Weighted™ Index (NASDAQ:NDXE) prior to market open on Monday, July 22, 2024. Super Micro Computer Inc. will replace Walgreens Boots Alliance Inc. (NASDAQ:WBA) in the Nasdaq-100 Index® and the Nasdaq-100 Equal Weighted Index. Walgreens Boots Alliance Inc. will also be removed from the Nasdaq-100 Ex-Tech Sector™ Index (NASDAQ:NDXX), the Nasdaq-100 ESG™ Index (NASDAQ:NDXESG), and the Nasdaq-100 Sustainable ESG Select™ Index (NASDAQ:NDXSES) on the same date. Super Micro Computer Inc
For Immediate Release: September 12, 2023 The U.S. Food and Drug Administration has issued warning letters to eight companies for manufacturing or marketing unapproved ophthalmic drug products in violation of federal law. These warning letters are part of the agency’s ongoing effort to protect Americans from potentially harmful ophthalmic products. Eye products addressed in the eight warning letters are illegal
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)